Celon Pharma (LTS:0RKX) Other Long Term Assets: zł188.2 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RKX Celon Pharma SA LTS:0RKX
23 GF Score
Price zł22.50
! 3 Warning Signs
View Full Analysis

What is Celon Pharma Other Long Term Assets?

Celon Pharma LTS:0RKX 23 Other Long Term Assets is zł188.2 Mil as of Mar. 2026. GuruFocus rates LTS:0RKX with a GF Score™ of 23/100. The stock has 3 warning signs investors should review.

Celon Pharma's other long-term assets for the quarter that ended in Mar. 2026 was zł188.2 Mil.

Celon Pharma's quarterly other long-term assets increased from Sep. 2025 (zł49.7 Mil) to Dec. 2025 (zł457.5 Mil) but then stayed the same from Dec. 2025 (zł457.5 Mil) to Mar. 2026 (zł188.2 Mil).

Celon Pharma's annual other long-term assets increased from Dec. 2023 (zł30.8 Mil) to Dec. 2024 (zł543.8 Mil) but then declined from Dec. 2024 (zł543.8 Mil) to Dec. 2025 (zł457.5 Mil).

Celon Pharma Other Long Term Assets Historical Data

* Premium members only.

The historical data trend for Celon Pharma's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celon Pharma Other Long Term Assets Chart

Celon Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 70.06 41.76 30.79 543.80 457.46

Celon Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 63.26 34.80 49.72 457.46 188.22
LTS:0RKX
23GF Score
Celon Pharma SA LTS:0RKX
Other Long Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Celon Pharma Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Frequently Asked Questions Learn more about Other Long Term Assets →
What does a Other Long Term Assets of zł188.2 Mil mean?
Celon Pharma (LTS:0RKX) has a Other Long Term Assets of zł188.2 Mil as of Mar. 2026. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Celon Pharma and its competitors.
Is Celon Pharma's Other Long Term Assets too high?
Celon Pharma's current Other Long Term Assets is zł188.2 Mil. Overall, Celon Pharma has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Celon Pharma's Other Long Term Assets compare to ZTS and UTHR?
Celon Pharma's Other Long Term Assets of zł188.2 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long Term Assets for a Drug Manufacturers company?
A good Other Long Term Assets depends on the Drug Manufacturers industry context. However, Other Long Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long Term Assets mean?
A high Other Long Term Assets can signal that a stock is expensive relative to its fundamentals. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Celon Pharma and its competitors. Celon Pharma's current Other Long Term Assets is zł188.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celon Pharma stock overvalued right now?
Celon Pharma (LTS:0RKX) has a current Other Long Term Assets of zł188.2 Mil. The current Other Long Term Assets is zł188.2 Mil. Celon Pharma's overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long Term Assets calculated?
Other Long Term Assets is calculated from a company's financial statements. For Celon Pharma (LTS:0RKX), the current Other Long Term Assets is zł188.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Celon Pharma Business Description

Other Exchanges CLN:Poland8RP:Germany
Address Ogrodowa 2A, Kielpin, Lomianki, POL, 05-092
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
23GF Score

Get the complete analysis for LTS:0RKX

Other Long Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł22.50
Price